
Sign up to save your podcasts
Or
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
4.5
183183 ratings
What happens when Intermountain Healthcare invests resources in an innovative precision medicine unit to provide life-extending, genetically targeted therapies to late-stage cancer patients? Harvard Business School professors Richard Hamermesh and Kathy Giusti discuss their case — entitled “Intermountain Healthcare: Pursuing Precision Medicine” — and its connections to their work with the Kraft Precision Medicine Accelerator.
249 Listeners
1,161 Listeners
376 Listeners
1,113 Listeners
108 Listeners
1,407 Listeners
746 Listeners
108 Listeners
175 Listeners
35 Listeners
771 Listeners
635 Listeners
221 Listeners
73 Listeners
81 Listeners
138 Listeners
76 Listeners